BURZYNSKI RESEARCH INSTITUTE INC
CIK 724445fmd_1F9H4XTDATMEZ5XKXBQ22CASWPManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Mar 01, 2010 to Nov 30, 2025, 62 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total operating expenses | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Operating income | (2) | (2) | (2) | (2) | (2) | (1) | (1) | (1) | (1) | (1) |
| Income before taxes | (2) | (2) | (2) | (2) | (2) | (1) | (1) | (1) | (1) | (1) |
| Income tax expense | 0 | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (2) | – | – | – | (2) | (1) | (1) | (1) | (1) | (1) |
| Net income | – | – | – | – | – | – | – | (1) | (1) | (1) |
| Net income to common shareholders | (2) | (2) | (2) | (2) | (2) | (1) | (1) | (1) | – | – |